Accumulating data had demonstrated that activation of the cGAS-STING pathway is crucial in the TME, and the benefit of induced tumor regression and increased survival time in preclinical studies and clinical trials had been achieved by STING agonists administration [24–26]. The gene discussed is CGAS; the disease is neoplasm.